DK1616012T3 - Lentivirale vektorer bærende syntetiske bidirektionelle promotorer og anvendelser deraf - Google Patents

Lentivirale vektorer bærende syntetiske bidirektionelle promotorer og anvendelser deraf

Info

Publication number
DK1616012T3
DK1616012T3 DK04728627T DK04728627T DK1616012T3 DK 1616012 T3 DK1616012 T3 DK 1616012T3 DK 04728627 T DK04728627 T DK 04728627T DK 04728627 T DK04728627 T DK 04728627T DK 1616012 T3 DK1616012 T3 DK 1616012T3
Authority
DK
Denmark
Prior art keywords
applications
lentiviral vectors
vectors bearing
bidirectional promoters
synthetic bidirectional
Prior art date
Application number
DK04728627T
Other languages
English (en)
Inventor
Luigi Naldini
Mario Amendola
Elisa Vigna
Original Assignee
San Raffaele Centro Fond
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by San Raffaele Centro Fond filed Critical San Raffaele Centro Fond
Application granted granted Critical
Publication of DK1616012T3 publication Critical patent/DK1616012T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Detergent Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK04728627T 2003-04-24 2004-04-21 Lentivirale vektorer bærende syntetiske bidirektionelle promotorer og anvendelser deraf DK1616012T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46508003P 2003-04-24 2003-04-24
PCT/IT2004/000227 WO2004094642A2 (en) 2003-04-24 2004-04-21 Lentiviral vectors carrying synthetic bi-directional promoters and uses thereof

Publications (1)

Publication Number Publication Date
DK1616012T3 true DK1616012T3 (da) 2008-04-21

Family

ID=33310991

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04728627T DK1616012T3 (da) 2003-04-24 2004-04-21 Lentivirale vektorer bærende syntetiske bidirektionelle promotorer og anvendelser deraf

Country Status (10)

Country Link
US (1) US8501464B2 (da)
EP (1) EP1616012B1 (da)
JP (1) JP2006524051A (da)
AT (1) ATE381620T1 (da)
AU (1) AU2004233315A1 (da)
CA (1) CA2523138C (da)
DE (1) DE602004010799T2 (da)
DK (1) DK1616012T3 (da)
ES (1) ES2298745T3 (da)
WO (1) WO2004094642A2 (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2002003T3 (da) * 2005-05-27 2016-03-21 Ospedale San Raffaele Srl Genvektor omfattende miRNA
US20100304378A1 (en) * 2007-09-17 2010-12-02 Universite De Strasbourg Method for Detecting or Quantifying a Truncating Mutation
DK2379722T3 (da) 2008-12-16 2017-01-02 C-Lecta Gmbh Ekspressionsvektor
EP2425001A4 (en) * 2009-04-30 2012-11-14 Univ California ANTI-HIV COMBINATION VECTORS, TARGETING VECTORS AND METHOD OF USE
US9719146B2 (en) * 2009-09-09 2017-08-01 General Electric Company Composition and method for imaging stem cells
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
CN101851637B (zh) * 2010-01-15 2011-12-14 中国农业科学院北京畜牧兽医研究所 一种制备同时表达多个基因的转基因动物的方法
WO2012004778A1 (en) * 2010-07-09 2012-01-12 Ecole Polytechnique Federale De Lausanne (Epfl) Method for in-vitro monitoring of neuronal disorders and use thereof
WO2013078433A1 (en) 2011-11-23 2013-05-30 University Of Hawaii Auto-processing domains for polypeptide expression
RS61387B2 (sr) 2013-02-15 2024-06-28 Bioverativ Therapeutics Inc Gen optimizovanog faktora viii
AU2014235968B2 (en) 2013-03-21 2018-05-24 Ospedale San Raffaele Srl Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
AU2016249798B2 (en) * 2015-04-14 2022-05-26 Janssen Vaccines And Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
US11174495B2 (en) 2015-12-04 2021-11-16 Board Of Regents, The University Of Texas System Reporter system for detecting and targeting activated cells
KR20180118659A (ko) 2016-02-01 2018-10-31 바이오버라티브 테라퓨틱스 인크. 최적화된 viii 인자 유전자
KR102673203B1 (ko) 2016-04-20 2024-06-10 센트로 데 인베스띠가씨오네스 에너제티까스 메디오암비엔딸레스 와이 테크놀로지까스, 오.에이., 엠.피. Pklr의 유전자 발현 증강을 위한 조성물 및 방법
KR101864581B1 (ko) * 2016-11-04 2018-07-13 국립암센터 양방향 프로모터를 포함하는 렌티바이러스 발현 벡터 및 이의 용도
WO2018127585A1 (en) 2017-01-06 2018-07-12 Txcell Monospecific regulatory t cell population with cytotoxicity for b cells
EP3346001A1 (en) 2017-01-06 2018-07-11 TXCell Monospecific regulatory t cell population with cytotoxicity for b cells
MX2020001593A (es) 2017-08-09 2020-07-13 Bioverativ Therapeutics Inc Moleculas de acido nucleico y usos de las mismas.
KR102742220B1 (ko) 2017-09-19 2024-12-17 더 유니버시티 오브 브리티쉬 콜롬비아 항-hla-a2 항체 및 그 사용 방법
US11814432B2 (en) 2017-09-20 2023-11-14 The University Of British Columbia Anti-HLA-A2 antibodies, related chimeric antigen receptors, and uses thereof
AU2018352583B2 (en) 2017-10-16 2025-04-17 Centro de Investigaciones Energeticas, Medioambientales Y Tecnologicas, O.A., M.P. Lentiviral vectors for delivery of PKLR to treat Pyruvate Kinase Deficiency
US11738047B2 (en) 2017-12-12 2023-08-29 The Trustees Of The University Of Pennsylvania Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof
US20210038744A1 (en) 2018-02-01 2021-02-11 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor viii
US12539316B2 (en) 2018-04-11 2026-02-03 Spacecraft Seven, Llc Compositions and methods for stem cell transplant
MX2020010808A (es) 2018-04-13 2021-03-02 Sangamo Therapeutics France Receptor de antigeno quimerico especifico para el receptor de interleucina-23.
IL278213B2 (en) 2018-04-27 2026-04-01 Rocket Pharmaceuticals Ltd A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd)
IL280465B2 (en) 2018-07-30 2025-03-01 Centro De Investig Energeticas Medioambientales Y Tecnologicas O A M P Methods for gene modification of hematopoietic cells
JP7602454B2 (ja) 2018-08-09 2024-12-18 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
SG11202101415UA (en) 2018-08-10 2021-03-30 Sangamo Therapeutics France New car constructs comprising tnfr2 domains
WO2020081759A1 (en) * 2018-10-17 2020-04-23 Texas Tech University System Multivalent virus like particle vaccines
GB201817821D0 (en) 2018-10-31 2018-12-19 Ospedale San Raffaele Srl TCR and peptides
US12668812B2 (en) 2018-11-20 2026-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Recombinant vectors suitable for the treatment of IPEX syndrome
CA3121786A1 (en) 2018-12-06 2020-06-11 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor ix
EP3980035A4 (en) 2019-06-07 2023-08-23 The Board Of Trustees Of The Leland Stanford Junior University GENETICALLY MODIFIED CD4+ T LYMPHOCYTES FOR USE IN TREG-BASED IMMUNOTHERAPY
JP7803014B2 (ja) 2019-09-30 2026-01-21 バイオベラティブ セラピューティクス インコーポレイテッド レンチウイルスベクター製剤
EP3808766A1 (en) 2019-10-15 2021-04-21 Sangamo Therapeutics France Chimeric antigen receptor specific for interleukin-23 receptor
EP4103591A4 (en) 2020-02-13 2024-09-04 The Board of Trustees of the Leland Stanford Junior University Crispr-based foxp3 gene engineered t cells and hematopoietic stem cell precursors to treat ipex syndrome patients
US20230147657A1 (en) 2020-03-20 2023-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Chimeric antigen receptor specific for human cd45rc and uses thereof
JP2023537565A (ja) 2020-06-24 2023-09-04 バイオベラティブ セラピューティクス インコーポレイテッド タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第ｖｉｉｉ因子を除去する方法
WO2022032226A1 (en) 2020-08-07 2022-02-10 Spacecraft Seven, Llc Plakophilin-2 (pkp2) gene therapy using aav vector
AU2021330936A1 (en) 2020-08-23 2023-05-04 Bioverativ Therapeutics Inc. MODIFIED BACULOVIRUS SYSTEM FOR IMPROVED PRODUCTION OF CLOSED-ENDED DNA (ceDNA)
CN113106091B (zh) * 2021-03-04 2022-08-16 杭州师范大学 一种植物叶片高表达双向启动子及其应用
WO2023028440A2 (en) 2021-08-23 2023-03-02 Bioverativ Therapeutics Inc. Baculovirus expression system
US20230084036A1 (en) 2021-08-23 2023-03-16 Bioverativ Therapeutics Inc. Optimized factor viii genes
IL311185A (en) 2021-09-03 2024-04-01 Sangamo Therapeutics Inc MOG-binding proteins and uses thereof
EP4408894A4 (en) * 2021-09-29 2025-08-20 Chimera Bioengineering Inc Compositions and methods for anti-tnmuc1 gold car t-cells
KR20240067122A (ko) 2021-09-30 2024-05-16 바이오버라티브 테라퓨틱스 인크. 감소된 면역원성을 갖는 인자 viii 폴리펩타이드를 암호화하는 핵산
US20250197888A1 (en) * 2022-03-24 2025-06-19 Cell & Brain Co., Ltd. Novel recombinant vector and use thereof
KR102632204B1 (ko) * 2022-03-24 2024-02-02 (주)셀레브레인 신규 재조합 벡터 및 이의 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6136597A (en) * 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
CA2309555A1 (en) 1997-12-12 1999-06-24 Adam Sampson-Johannes Selective killing and diagnosis of p53+ neoplastic cells
JP2002508338A (ja) 1997-12-12 2002-03-19 ナルディニ，ルイジ レンチウィルスベクターの治療使用
AU1905200A (en) 1998-11-13 2000-06-05 Cell Genesys, Inc. A sensitive screening system for envelope-defective recombinant virus
CA2349617C (en) 1998-11-13 2015-04-28 Miltenyi Biotec B.V. & Co. KG Selection system for generating efficient packaging cells for lentiviral vectors
CA2370108A1 (en) 1999-04-30 2000-11-09 Advance Sentry Corporation System and method for screening of nasopharyngeal carcinoma
US6630324B1 (en) * 1999-07-29 2003-10-07 Baylor College Of Medicine Aldehyde reductase bidirectional promoter and its use
US6780639B1 (en) * 1999-08-24 2004-08-24 Universite Libre De Bruxelles Antibiotic inducible/repressible genetic construct for gene therapy or gene immunization
AU2001278430A1 (en) 2000-05-22 2001-12-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Systemic and cardiovascular transduction with lentiviral vectors
JP2003033179A (ja) * 2001-07-05 2003-02-04 Asahi Kasei Corp 可逆的遺伝子導入ベクター
WO2003087294A2 (de) * 2002-04-15 2003-10-23 Universitätsklinikum Hamburg-Eppendorf Rekombinante virale vektoren zur tetracyclinregulierbaren genexpression

Also Published As

Publication number Publication date
DE602004010799T2 (de) 2009-01-22
ATE381620T1 (de) 2008-01-15
JP2006524051A (ja) 2006-10-26
CA2523138A1 (en) 2004-11-04
US8501464B2 (en) 2013-08-06
US20060200869A1 (en) 2006-09-07
AU2004233315A1 (en) 2004-11-04
WO2004094642A3 (en) 2005-05-12
ES2298745T3 (es) 2008-05-16
EP1616012A2 (en) 2006-01-18
DE602004010799D1 (de) 2008-01-31
EP1616012B1 (en) 2007-12-19
WO2004094642A2 (en) 2004-11-04
CA2523138C (en) 2013-04-23

Similar Documents

Publication Publication Date Title
DE602004010799D1 (de) Synthetische bidirektionale promotoren und deren verwendungen
BRPI0417825A (pt) métodos para uso de lactobacilli probióticos para animais de estimação
BRPI0417823A (pt) métodos para uso de bifidobactérias probióticas para animais de estimação
AU2003295600A8 (en) Functional and hyperfunctional sirna
ATE393169T1 (de) Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung
CY1110868T1 (el) Ελαχιστη αλληλουχια dna που δρα ως μονωτης της χρωματινης και η χρηση της στην πρωτεϊνικη εκφραση
CY1110557T1 (el) Αντισωματα ιντερλευκινης-10
DE602004026113D1 (de) Glp-1-verbindungen
DK1546316T3 (da) Mutant E. Coli-AppA-fytaseenzymer og naturlige varianter deraf, nukleinsyrer, der koder for sådanne fytaseenzymer, vektorer og værtsceller, som inkorporerer disse og fremgangsmåder til at fremstille og anvende disse
DK1585737T3 (da) Uraciler med herbicid virkning
DE60138715D1 (de) Tnf-rezeptor-ähnliche moleküle und deren anwendungen
DE60031395D1 (de) Mikrobielle beta-glukuronidase gene, genprodukte und deren verwendungen
ATE419265T1 (de) Benzoat- und antranilatinduzierbare promotoren
ATE473238T1 (de) Tuberkulose vaccine mit verbesserter effizienz
BR0313988A (pt) Escova de dentes e uso de uma escova de dentes
NZ334839A (en) Polynucleotide molecules encoding neospora proteins and uses thereof
ATE404602T1 (de) Wässrige polyurethanzubereitungen
GB0205378D0 (en) Bacterial spores
ATE429443T1 (de) Nukleinsäuresequenz, die für das opca gen kodiert
SE0300101L (sv) Upphängningsanordning för arbetsredskap
ES2421558T3 (es) Anticuerpos específicos de cáncer y proteínas de superficie celular
DK1664102T3 (da) Isoleret photoprotein mtclytin, samt dets anvendelse
WO2003091447A3 (en) D1-1 nucleic acids, polypeptides and related methods
WO2005057486A3 (en) Protein engineering with analogous contact environments
RU2003103720A (ru) Штамм бактерий bacillus pantothenticus 1-85 для использования в гранулированных кормах